Figure 5.

Diabody-mp exhibits improved tumor inhibition compared with other structural antibodies and single or combined c-Met and PD-1 blockade therapy. a Individual tumor growth curve. BALB/c mice were inoculated with MKN45 cells and treated as indicated for a month from day 10. The tumor growth was monitored at the indicated times point. n = 5 mice per group. b Representative images of immunohistochemical staining of CD8⁺ performed on MKN45 tumors treated as indicated; scale bar, 100 µm. c Quantification of IFN-γ secreted in the blood and tumor microenvironment of mice bearing the MKN45 tumors and treated as indicated. d Tumor growth curves of MKN45 gastric carcinoma in BALB/c mice treated with diabody-mp (1 mg/kg, once-daily, i.p.), capmatinib (10 mg/kg, once-daily, i.g.), toripalimab (10 mg/kg, once-weekly, i.v.) or capmatinib combined with toripalimab for a month. n = 8 mice per group. e Immunostaining of CD8 (CTL marker) and granzyme B (activity of T cell) in the MKN45 tumor sections; scale bar, 100 µm. f Mice survival curves were generated from MKN45-bearing mice. n = 8 mice per group